Neuronetics Delivers 500th NeuroStar TMS System for Treating Depression

MALVERN, PA, August 8, 2013 – Neuronetics, Inc., the market leader in Transcranial Magnetic Stimulation technology for the treatment of Major Depressive Disorder, announced today that more than 500 of its NeuroStar TMS Therapy® Systems are now installed and available to treat adult depression patients throughout the U.S.
 
More than 13,000 US patients have been treated with NeuroStar, a non-invasive, non-drug therapeutic device that delivers highly-focused magnetic pulses to stimulate and activate neurons in localized regions of the brain. NeuroStar’s TMS precision pulse technology directly stimulates the left prefrontal cortex, a region of the brain known to be inactive in patients with depression, and also activates deep brain structures involved in mood regulation.
 
“This milestone of 500-plus NeuroStar installations is truly gratifying since it represents accelerating acceptance of this safe, effective alternative to oral antidepressants among both patients and their physicians’” said Bruce Shook, CEO of Neuronetics, Inc. “Multiple studies have demonstrated the safety and efficacy of NeuroStar’s targeted therapy in patients for whom medications don’t work, and without the systemic side effects so commonly produced by antidepressant drugs. We believe that in partnership with the physicians using NeuroStar, we are rapidly changing the face of depression treatment and improving the lives of thousands of patients in the US and overseas.”
 
 
About Depression
Depression is a serious illness that affects about 121 million people worldwide, according to the World Health Organization. People with depression may experience a range of physically and emotionally debilitating symptoms, including anxiety, sadness, irritability, fatigue, changes in sleep patterns, loss of interest in previously enjoyable activities and digestive problems.
 
About NeuroStar TMS Therapy®
NeuroStar TMS Therapy is a non-systemic (does not circulate in the bloodstream throughout the body) and non-invasive (does not involve surgery) form of neuromodulation. It stimulates nerve cells in an area of the brain that has been linked to depression by delivering highly- focused MRI-strength magnetic field pulses. The treatment is typically administered daily for 4-6 weeks. NeuroStar TMS Therapy is available by prescription only. There is a rare risk of seizure associated with TMS (less than 0.1% per acute treatment course). For full safety and prescribing information, visit www.NeuroStar.com.
 
About Neuronetics
Neuronetics, Inc. is a privately-held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. Based in Malvern, PA, Neuronetics is the leader in the development of TMS Therapy, a non-invasive form of neuromodulation. Neuronetics was created as a spin-out of The Innovation Factory, a medical device incubator in Duluth, GA. For more information, please visit www.neuronetics.com.
 
NeuroStar®, NeuroStar TMS Therapy® and TMS Therapy® are registered trademarks of Neuronetics, Inc.



53-51055-000 Rev A

Contact Information

Sue McMonigle

Vice President, Marketing

Neuronetics, Inc.

(1) Office: 610-981-4153 Cell: 215-527-4205

smcmonigle@neuronetics.com